Árpád Szöőr

The combination of trastuzumab and pertuzumab administered at approved doses may delay development of trastuzumab resistance by additively enhancing antibody-dependent cell-mediated cytotoxicity

Gábor Tóth, Árpád Szöőr, L Simón et al. · mAbs · 2016 · 104 citations · Full text

Medicine, Oncology, Pharmacology +17

Trastuzumab derived HER2-specific CARs for the treatment of trastuzumab-resistant breast cancer: CAR T cells penetrate and eradicate tumors that are not accessible to antibodies

Árpád Szöőr, Gábor Tóth, Barbara Zsebik et al. · Cancer Letters · 2020 · 100 citations · Full text

Medicine, Immunology, Oncology +17

CD123-Engager T Cells as a Novel Immunotherapeutic for Acute Myeloid Leukemia

Challice L. Bonifant, Árpád Szöőr, David Torres et al. · Molecular Therapy · 2016 · 83 citations · Full text

Life Sciences, Hematology, Immunology +17

T cells expressing CD19-specific Engager Molecules for the Immunotherapy of CD19-positive Malignancies

Mireya Paulina Velasquez, David Torres, Kota Iwahori et al. · Scientific Reports · 2016 · 57 citations · Full text

Life Sciences, Immunology, Oncology +17

TCRs Genetically Linked to CD28 and CD3ε Do Not Mispair with Endogenous TCR Chains and Mediate Enhanced T Cell Persistence and Anti-Melanoma Activity

Coen Govers, Zsolt Sebestyén, Mandy van Brakel et al. · The Journal of Immunology · 2014 · 46 citations · Full text

Life Sciences, Cell Biology, Immunology +17